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Abstract
Objectives—The impact of taking oral glucose-lowering medicines intermittently, rather than as 
recommended, is unclear. We conducted a retrospective cohort study using community-acquired 
United Kingdom clinical data (CPRD and GoDARTS databases) to examine the prevalence of 
non-adherence to treatment for type 2 diabetes, and investigate its potential impact on HbA1c 
reduction stratified by type of glucose-lowering medication.
Research design and methods—Data for patients treated between 2004 and 2014 were 
extracted for those newly-prescribed metformin, sulfonylurea, thiazolidinedione or dipeptidyl 
peptidase-4 inhibitors who continued to obtain prescriptions over one year, were extracted. 
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Cohorts were defined by prescribed medication type, and good adherence as a medication 
possession ratio ≥0.8. Linear regression was used to determine potential associations between 
adherence and one-year baseline-adjusted HbA1c reduction.
Results—In CPRD and GoDARTS, 13% and 15% of patients respectively were non-adherent. 
Proportions of non-adherent patients varied by the oral glucose-lowering treatment prescribed 
(range 8.6% (thiazolidinedione) to 18.8% (metformin)). Non-adherent, compared with adherent, 
patients had a smaller HbA1c reduction (0.4%[4.4mmmol/mol] and 0.46%[5.0mmol/mol] for 
CPRD and GoDARTs respectively). Difference in HbA1c response for adherent compared with 
non-adherent patients varied by drug (range: 0.38%[4.1mmol/mol] to 0.75%[8.2mmol/mol] lower 
in adherent group). Decreasing levels of adherence were consistently associated with a smaller 
reduction in HbA1c.
Conclusions—Reduced medication adherence for commonly used glucose lowering therapies 
among patients persisting with treatment is associated with smaller HbA1c reductions, compared 
with those taking treatment as recommended. Differences observed in HbA1c responses to glucose 
lowering-treatments may be explained in part by their intermittent use.
Keywords
type 2 diabetes; adherence; HbAlc; oral glucose lowering treatment; retrospective cohort
Between a third and a half of medicines prescribed for type 2 diabetes (T2DM), a condition 
in which multiple medications are used to control cardiovascular risk factors and blood 
glucose [1,2], are not taken as prescribed [3–6]. However, estimates vary widely depending 
on the population being studied and the way in which adherence to recommended treatment 
is defined.
The impact of continuing to take glucose lowering medicines intermittently, but not as 
recommended is unknown. Medication possession (expressed as a ratio of actual compared 
to expected possession), derived from prescribing records has been identified as a valid 
adherence measure for people with diabetes [7]. Previous studies have been limited to small 
populations in managed care systems in the United States and focused on metformin and 
sulfonylurea oral glucose-lowering treatments [8,9]. Further studies need to be carried out in 
larger groups of people that are more representative of the general population.
The Clinical Practice Research Database (CPRD) is a long established repository of routine 
clinical data from over 13 million patients registered with primary care services in the 
England. These data now include demographic data, diagnostic codes, biochemistry results 
and prescribing records from clinicians that have achieved high standards of data 
completeness. The GoDARTS database is derived from integrated health records in Scotland 
with primary care, pharmacy and hospital data on 9400 patients with diabetes.
We sought to establish the prevalence of medication non-adherence, measured from 
routinely collected data in patients with T2DM, and its relationship to reductions in glycated 
hemoglobin (HbA1c) with prescribed glucose-lowering medications. Specifically, we wished 
to determine whether poor response to oral glucose-lowering drugs could be due in part to 
reduced adherence. We hypothesized that there would be an association between the number 
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of tablets potentially available for a newly prescribed glucose-lowering medication (if all 
prescriptions were filled) over one year (expressed as a percentage) and the observed 
reduction in HbA1c.
Research Design and Methods
Design
We performed a retrospective cohort study using routine clinical data obtained from 
community-acquired United Kingdom clinical data. The primary endpoint of the study was 
HbA1c reduction over one year.
Data sources
We selected patients from the Clinical Practice Research Datalink (CPRD) and the 
GoDARTS cohort. CPRD contains anonymized longitudinal health records from 680 general 
practices across the UK amounting to 13.2 million patients [10]. We selected patients 
prescribed metformin, sulfonylurea, dipeptidyl peptidase-4 inhibitors (DPP4i), or 
thiazolidinediones. Prescriptions for glucagon-like peptide 1 receptor agonists (GLP-1 RA) 
were not included in the analysis given the limited information available and difficulty in 
determining daily doses for injectable therapies.
GoDARTS contains electronic health record data from primary care, hospitals and 
pharmacies [11]. It includes over 9,400 patients with T2DM who have given explicit consent 
for use of the information in research. In addition to the types of data available through 
CPRD, it includes information on the dispensing of prescribed medication.
Population
In both data-sets the date of diagnosis was based on the earliest record of either a first 
prescription of a glucose lowering drug prescribed, a diabetes diagnostic code or the first 
HbA1c>6.5% [48mmol/mol]. Patients were included in a cohort for analysis if there was a 
record of treatment with a glucose-lowering medication for a period of at least one year
Patients were excluded from the analysis if they: were younger than 35 years old when 
diagnosed; had forms of diabetes other than T2DM, including gestational diabetes; had a 
diabetes duration <1 year; had previously been prescribed or were currently taking insulin; 
or were prescribed a thiazolidinedione or a DPP4i as monotherapy (where the characteristics 
of patients prescribed these treatments as monotherapy differed from other treatments and 
treatment combinations). We restricted consideration to the first period of treatment on each 
drug for each person. An individual patient could contribute 12-month periods of 
observation for different drugs, but could not contribute data for two or more drugs 
concurrently.
Derived variables
The medication possession ratio (MPR) was calculated by using prescription data (or for 
GoDARTS the dispensing data) from the date of the first prescription for that patient to the 
next prescription after 365 days from the first prescription date. The one year period for 
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calculating adherence was considered valid if: i) there were no gaps between prescriptions 
longer than 6 months (a gap of more than 6 months was considered “stopping” the drug); ii) 
there was no change in treatment (either a drug being started or stopped) in the period of 
three months prior to the drug start date up until the date of the first prescription after one 
year, and iii) data were available from three or more prescriptions (with non-zero daily dose 
information). MPR was defined as the number of days of available medication divided by 
the number of days between the first and last prescription dates, multiplied by 100. The 
number of days of available medication was calculated by dividing the quantity prescribed 
by the daily dose. In some instances (25% of 15,336,948 prescription records in CPRD) the 
daily dose was recorded as zero. Where dose information was not available for any of the 
prescriptions for a patient over the 12-month prescription period, MPR was not calculated. 
For those where there were at least three valid prescriptions, but dose was missing from 
others, we removed the prescription with missing dose and the time between that 
prescription and the next from the denominator (seven per cent of cases). Patients with MPR 
≥120% were excluded from the analysis.
HbA1c response at one year—Baseline HbA1c was the closest HbA1c value to the drug 
start date in a time-window between three months before to seven days after. The twelve-
month HbA1c values used were those nearest to the date one year after the drug was started, 
with a time window from three months before to three months after. Response was 
calculated as 12 month HbA1c minus baseline HbA1c. For the response to be valid, there 
had to be no change in treatment (either a drug being started or stopped) in the period from 
the baseline HbA1c date to the twelve-month HbA1c date. Invalid responses were excluded 
from analysis. Response could not be calculated on 6% patients due to missing HbA1c data.
Additional clinical variables—We extracted age and body mass index (BMI), from the 
data as baseline variables at the time a glucose-lowering drug was started. The values used 
were those that were the closest to the drug start date in a time-window between six months 
before to seven days after. Medication doses over one year were calculated as a mean 
percentage maximum dose for that medication, weighted by the number of days the patient 
was on that dose.
Statistical Analyses
We categorized adherence into MPR groups; <70%, 70 to <80%, 80 to <90%, 90 to <100%, 
>100%. For the analyses presented here we defined non-adherence as a MPR <80% and 
adherence as a MPR ≥80% [12]. .
To assess the impact of MPR category on response we used regression models, adjusted for 
baseline HbA1c, for each drug, and all data combined. Models used MPR category (coded as 
a factor) and baseline HbA1c as independent variables and change in HbA1c over 12 months 
as the outcome. Only baseline HbA1c was adjusted for, as this explains the most variation in 
response (R2=0.32). We did not adjust for other features in these models. For each drug and 
overall we plotted 95% confidence intervals for change in HbA1c adjusted by baseline 
HbA1c and p values for comparison of the extreme categories were derived from the 
regression analysis. All analyses were carried out in R version 3.0.2 [13].
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Ethics
Approval for the study was granted by the CPRD Independent Scientific Advisory 
Committee (ISAC 13_177R) and for GoDARTS by the East of Scotland Regional Ethics 
Committee (09/21402/44).
Role of the funding source
The funder of the trial had no role in study design, data collection, data analysis, data 
interpretation or writing of the report.
Results
Analysis of CPRD dataset
32,634 patients were included for analysis with 38,100 instances of starting a new treatment 
(periods of treatment) and continuing for at least one year. The characteristics of included 
patients are shown by treatment cohort in Table 1. The mean duration of diabetes was 
shorter for those on the metformin and sulfonylurea cohorts, consistent with use of 
metformin earlier in the course of the disease. The mean proportion of the maximum dose of 
each drug also varied by treatment. Overall, 28.7% of patients were taking no other non-
insulin glucose lowering treatments, 51.8% were taking one other treatment and 19.1% were 
taking two other treatments (Supplementary Table 1). Additional glucose lowering drug 
treatment for patients in each cohort is shown in Supplementary Table 2, with the majority 
taking metformin alongside other treatments.
The proportion of non-adherent patients was 13.3% (n=38,100 periods of treatment; 32,634 
patients), ranging from 9.1% and 8.6% for DPP4i inhibitors and thiazolidinediones 
respectively up to 18.8% with metformin (Table 2). For all therapies, participants with MPRs 
≥90% experienced the greatest reductions in baseline-adjusted HbA1c (Figure 1). With lower 
MPRs, there was a consistent observed smaller reduction in HbA1c changes with all 
therapies (Figure 1).
Adherent, compared with non-adherent, patients consistently had greater HbA1c reductions 
in all drug classes (Table 2). Overall, HbA1c decrements (95% CI) were -0.75 (-0.78 to 
-0.72)% [-8.2 (-8.5 to -7.9)] mmol/mol) and -1.15 (-1.16 to -1.14)% [-12.5 (-12.7 to -12.4) 
mmol/mol] for non-adherent and adherent patients respectively (Table 2). The mean (95% 
CI) difference overall between adherent and non-adherent groups in baseline-adjusted one-
year HbA1c was -0.40 (-0.43 to -0.37) % [-4.4 (-4.7 to -4.0) mmol/mol]. This between-group 
difference varied across drugs from -0.37 (-0.44 to -0.31)% [-4.1 (-4.8, -3.4) mmol/mol] 
with sulfonylureas to -0.57 (-0.64 to -0.49)% [-6.2 (-7.0, -5.4) mmol/mol] with 
thiazolidinediones (Table 2).
Analysis of GoDARTS cohort
2284 patients were included for analysis with 2622 instances of starting a new treatment 
(periods of treatment) and continuing for at least one year. The characteristics of included 
patients are shown by treatment cohort in Table 1 and, similarly to CPRD, the different 
characteristics of the cohort reflect the stage of treatment at which the treatment was started. 
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Overall, 34% of patients were taking no other non-insulin glucose lowering treatments, 44% 
were taking one other treatment and 22% were taking two other treatments (Supplementary 
Table 3 and 4).
The proportion of non-adherent patients was 15.1% (n=2622 periods of treatment; 2284 
patients) ranging from 10.7% with DPP4i up to 18.1% with metformin (Table 2). For all 
therapies, participants with an MPR≥90% experienced the greatest reductions in baseline-
adjusted HbA1c (Figure 1). With lower MPRs, there was a consistent observed smaller 
reduction in HbA1c across all therapies (Figure 1). There was no clear evidence of a 
differential response to any one therapy for groups of patients with differing MPR.
Overall HbA1c decrements were -0.67 (-0.79 to -0.55)% [6.9 (-8.1 to -5.7) mmol/mol] and 
-1.16 (-1.21 to -1.11)% [-11.9 (-12.5 to -11.4) mmol/mol] for non-adherent and adherent 
patients respectively (Table 2). The mean (95% CI) difference overall between adherent and 
non-adherent groups in baseline-adjusted one-year HbA1c was -0.49 (-0.62 to -0.36)% [-5.0 
(-6.3 to -3.7) mmol/mol]. This between-group difference varied across drugs from -0.34 
(-0.58 to -0.10)% [-3.7 (-6.3 to -1.5) mmol/mol] with sulfonylurea to -0.75 (-1.22 to -0.28)% 
[-8.2 (-13.3, -3.1) mmol/mol] with DPP4i (Table 2).
Conclusions
These findings show an association between adherence to oral glucose lowering treatment, 
measured by the proportion of medication obtained on prescription over one year, and the 
corresponding decrement in HbA1c, in a population of patients newly starting treatment and 
continuing to collect prescriptions. The association is consistent across all commonly used 
oral glucose lowering therapies and the findings are consistent between the two data sets 
examined, CPRD and GoDARTS. Non-adherent patients, taking on average less than 80% of 
the intended medication, had about half the expected reduction in HbA1c.
This is the largest study that we are aware of to examine the association between adherence 
to oral glucose lowering treatment in type 2 diabetes over one year and change in HbA1c. 
The study uses two independent datasets: a representative primary care data-set from across 
England and an electronic medical record data-set from a region in Scotland. Both data sets 
have detailed information about dosage adjustment over the period of the study[14] and 
include systematic records of clinical and laboratory measurements at three to six monthly 
intervals. Results were consistent across both studies. Although the Scottish data utilize 
prescription encashment, the similar results in CPRD support the use of issued prescription 
data for studying medication adherence.
There are a number of issues that could be further explored in greater depth to provide 
information about factors associated with non-adherence. These include whether adherence 
differs when a medication is used as first, second or third line, and the extent to which there 
is an interaction with the type of medication. In addition, there is potential for stating a drug 
to change adherence to other concurrent medication. However, because our study is limited 
by use of different populations in examining the different drugs, we are unable to directly 
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address these questions, and our study does not provide evidence of comparative 
effectiveness between the drugs.
Although direct comparisons of adherence rates are not possible, high adherence levels 
reported for patients taking drugs commonly found in combination therapy (e.g. DPP4i) may 
reflect a greater personal investment in disease self-management. Differences with baseline 
characteristics of patients using DPP4i between England and Scotland may reflect 
differences in local usage of the class of drugs, as there is no difference in national guidance. 
Similarly, the higher levels of change in HbA1c found for patients taking metformin and 
sulfonylurea may also reflect an earlier stage in the course of their diabetes.
There is the possibility for time-dependent confounding and this is something we have not 
explored in this paper. We have limited our data to only simple models, and those cases 
where there were no changes in diabetes drugs during the one-year period of interest. 
However, this does not exclude other potential changes that may impact on adherence, such 
as changes in dose, incidence of side effects, or changes in other medications or 
comorbidities. It will be of interest to examine predictors of adherence, both at baseline 
when starting medication, and over the time-course of taking the drug. Development of in 
depth models to explore this would be an important next step for further research focusing 
on the relationship between adherence and achieved HbA1c.
There are a number of different ways to measure adherence to medication. Overall 
adherence rates are consistently overestimated by self-report [15]. Direct measurement (for 
example with electronic dispensing measurement) has potential to modify behavior because 
it is intrusive. Data on medication prescribing and dispensing is widely used, has evidence to 
support its validity [7], and medicine availability is a necessary prerequisite for being able to 
take the medicine. Medication hoarding (obtaining medicine but not then using it) has been 
identified as an issue in the psychiatric literature, but not more generally for long-term 
conditions [16]. In another study, perceptions of higher levels of hoarding in older people 
relating to medicines’ non-adherence were not supported [17].
The focus of this study is on the relationship of quality of taking medication and impact on 
HbA1c. The Medication Possession Ratio is used to report adherence as an increasingly 
accepted measure of medicines use. There are some patterns of medication use that may 
result in misleading metrics for MPR, but the most common, failure to persist with 
medication is accounted for in this analysis by exclusion of patients with a six month or 
longer break in prescribing [18]. It also excludes individuals starting treatment in the first 
year after diagnosis, again a group where overall adherence and persistence is likely to differ 
from those at a later stage of their illness.
In addition, this retrospective study was not able to identify sufficient patients within the 
data set to provide information about GLP-1 RA treatment. We have not addressed 
adherence to insulin therapy in this analysis.
A number of previous studies have used retrospective databases of electronic health records 
to examine factors that might predict adherence. A recent large cohort database examined 
overall adherence to oral therapy for type 2 diabetes, taking into account changes of therapy. 
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It concluded that overall adherence was 69%, with individuals newly started on treatment 
being significantly less likely to adhere [19]. There are few studies providing estimates of 
adherence to treatment and its relationship to glycaemic control: we have identified only 
two, both focussed on sulfonylurea and metformin treatment, and of relatively small size. In 
one, based in south-west Michigan, 677 patients with diabetes were reviewed and a 10% 
increase in non-adherence was associated with a 0.14% (1.5 mmol/mol) rise in HbA1c [9]. A 
larger study in South Carolina of 1668 patients found that the mean medication possession 
ratio for those reaching an HbA1c target of 7.0% [53mmol/mol] was 81% [8].
Low medication adherence is related to increased mortality [20]. The mean difference in 
HbA1c between patients with MPR<80% and ≥80% is between 0.37 and 0.55% (4 and 
6mmol/mol), equivalent to up to a 10% reduction in death or an 18% reduction in diabetes 
complications [21]. The small numbers with adherence <70% mean that exploring the 
impact of this on HbA1c and its relationship to other lifestyle factors requires a larger study 
population. Further work is now needed to demonstrate the extent to which improved 
compliance leads to improvements in HbA1c.
Data obtained from real-time monitoring of medication collection may provide feedback to 
patients and their clinicians to indicate whether medication use might be sub-optimal. 
Further work is needed to establish the intervals over which data becomes meaningful and 
whether analysis with other routinely collected data improves identification of low 
adherence to treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Plot of HbA1c (mmol/mol) change over all drugs in 12 months for each data set by 
Medication Possession Ration (MPR) category (baseline adjusted absolute change in HbA1c)
“Difference in HbA1c change for both CPRD and DARTS p<0.00001)
Black circles = CPRD, white squares = GoDARTS
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